Christine O’Day

877 total citations
19 papers, 720 citations indexed

About

Christine O’Day is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Christine O’Day has authored 19 papers receiving a total of 720 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Hematology. Recurrent topics in Christine O’Day's work include DNA and Nucleic Acid Chemistry (4 papers), RNA modifications and cancer (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Christine O’Day is often cited by papers focused on DNA and Nucleic Acid Chemistry (4 papers), RNA modifications and cancer (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Christine O’Day collaborates with scholars based in United States and Japan. Christine O’Day's co-authors include John‐Stephen Taylor, Neil S. Cutshall, John Abelson, Gloria Dalbadie‐McFarland, Peter Burgers, Karl M. Ebert, Timothy Edmunds, Catherine Bartlett, John M. McPherson and Katherine Gordon and has published in prestigious journals such as Journal of the American Chemical Society, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Christine O’Day

19 papers receiving 700 citations

Peers

Countries citing papers authored by Christine O’Day

Since Specialization

Citations

This map shows the geographic impact of Christine O’Day's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine O’Day with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine O’Day more than expected).

Fields of papers citing papers by Christine O’Day

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine O’Day. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine O’Day. The network helps show where Christine O’Day may publish in the future.

Co-authorship network of co-authors of Christine O’Day

This figure shows the co-authorship network connecting the top 25 collaborators of Christine O’Day. A scholar is included among the top collaborators of Christine O’Day based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine O’Day. Christine O’Day is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	1187 Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors 2022 ·Regular and Young Investigator Award Abstracts ·(unknown), (unknown), Bernard A. Liu, (unknown), John J. Gosink, (unknown), (unknown), Kelly Hensley, (unknown), Albina Nesterova, (unknown), Anthony Cao, Christine O’Day, Ryan A. Heiser, Timothy S. Lewis, Shyra J. Gardai, (unknown), Masashi Shimazaki, (unknown), Sharsti Sandall	10
2	Abstract 1140: Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer 2022 ·Cancer Research ·(unknown), (unknown), (unknown), Anthony Lee, (unknown), Amit Garg, Christine O’Day, Esther S. Trueblood, Jennifer Wright, Mark Bieda, Charles W. Caldwell, Kelly Hensley, (unknown), Bernard A. Liu, Masashi Shimazaki, Sharsti Sandall	2
3	Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma 2021 ·Blood ·David R. Taft, Clark M. Henderson, Christine O’Day, Changpu Yu, (unknown), (unknown), Heather Van Epps	2
4	SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML 2015 ·Blood ·May S.K. Sutherland, Changpu Yu, Christine O’Day, (unknown), Martha E. Anderson, Kim K. Emmerton, (unknown), Megan M. O’Meara, Eric J. Feldman, Dana A. Kennedy, Maureen C. Ryan, Dennis R. Benjamin	8
5	Abstract 239: Biomarker profiling and combination studies of receptor tyrosine kinase inhibitors of EGFR, ERBB2, IGFR-1, FGFR and PDGFR 2011 ·Cancer Research ·Christine O’Day, (unknown), (unknown), (unknown), (unknown), (unknown)	2
6	Abstract 3590: Profiles of contributing genes to sensitive/resistant phenotypes of 11 different oncology therapeutic agents across 240 cell lines 2010 ·Cancer Research ·Christine O’Day, (unknown), (unknown), (unknown), (unknown), Phuong Nguyen, (unknown), (unknown), (unknown), Jenny Mulligan, (unknown), Shimin Wang	1
7	240 human tumor cell line profiling to evaluate relationships between tumor genotypes and cancer cell sensitivity 2010 ·Clinical Cancer Research ·Christine O’Day, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
8	Assessing cancer therapeutic agents across fifteen human tumor cell line panel 2008 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Christine O’Day	1
9	297 Distinct Cell Lines: A High-Content Analysis Assay and a Full-Automation Design Solely Using Noncontact Liquid Dispensing 2007 ·JALA Journal of the Association for Laboratory Automation ·(unknown), (unknown), Christine O’Day, Yulia Ovechkina, (unknown)	7
10	Rhodanine derivatives as inhibitors of JSP-1 2005 ·Bioorganic & Medicinal Chemistry Letters ·Neil S. Cutshall, Christine O’Day, (unknown)	172
11	Novel Lysine–Spermine Conjugate Inhibits Polyamine Transport and Inhibits Cell Growth When Given with DFMO 2000 ·Experimental Cell Research ·Reitha S. Weeks, Scott M. Vanderwerf, (unknown), Mark R. Burns, Christine O’Day, Feng Cai, Bruce H. Devens, Heather K. Webb	46
12	18S rRNA processing requires the RNA helicase-like protein Rrp3 1996 ·Nucleic Acids Research ·Christine O’Day	66
13	In Vitro Studies of the Prp9·Prp11·Prp21 Complex Indicate a Pathway for U2 Small Nuclear Ribonucleoprotein Activation 1996 ·Journal of Biological Chemistry ·(unknown), Christine O’Day, John Abelson	37
14	The Saccharomyces cerevisiae Prp5 Protein Has RNA-dependent ATPase Activity with Specificity for U2 Small Nuclear RNA 1996 ·Journal of Biological Chemistry ·Christine O’Day, Gloria Dalbadie‐McFarland, John Abelson	97
15	PCNA-induced DNA synthesis pastcis-syn andtrans-syn-l thymine dimers by calf thymus DNA polymeraseδ in vitro 1992 ·Nucleic Acids Research ·Christine O’Day, Peter Burgers, John‐Stephen Taylor	67
16	Transgenic Expression of a Variant of Human Tissue-Type Plasminogen Activator in Goat Milk: Purification and Characterization of the Recombinant Enzyme 1991 ·Nature Biotechnology ·(unknown), M. Anthony Hayes, Christine O’Day, Timothy Edmunds, Catherine Bartlett, (unknown), Karl M. Ebert, Katherine Gordon, John M. McPherson	72
17	Cis-syn thymine dimers are not absolute blocks to replication by DNA polymerase I of Escherichia coli in vitro 1990 ·Biochemistry ·John‐Stephen Taylor, Christine O’Day	61
18	Synthesis of bacteriophage DNA containing a site-specific cis-syn thymine dimer 1989 ·Journal of the American Chemical Society ·John‐Stephen Taylor, Christine O’Day	4
19	A building block for the sequence-specific introduction of cis-syn thymine dimers into oligonucleotides. Solid-phase synthesis of TpT[c,s]pTpT 1987 ·Journal of the American Chemical Society ·John‐Stephen Taylor, (unknown), Christine O’Day	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact